Address
890 Winter Street
Waltham, MA 02451
United States of America (the)
Phone
781 208 2466
Website
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
October 11, 2024
| Name | Title | Pay | Year Born |
| E. Rand Sutherland | Chief Executive Officer & Director | 1M | 1970 |
| Allison Ambrose | Senior Vice President, General Counsel & Secretary | 59,792 | 1985 |
| Michael Paul Gray | Chief Financial Officer & Chief Operating Officer | 706,300 | 1971 |
| Aaron Deykin | Chief Medical Officer and Head of Research & Development | 741,800 | 1967 |
| Adam Houghton | Chief Business Officer | 0 | 1971 |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations | 0 | N/A |
| Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
| Stacy Price | Chief Technology Officer | 0 | 1969 |
| Lisa Fiering | Senior Vice President of People & Culture | 0 | N/A |
| Fang Xie | Vice President & Head of Biometrics | 0 | N/A |
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.